top of page

WEIGHT LOSS MEDICATION DISCLAIMER (SEMAGLUTIDE & TIRZEPATIDE)

Last updated: July 2, 2025

General Medical Disclaimer
Semaglutide and Tirzepatide are prescription medications used as part of a medically supervised weight-management program. PharmXHealthOne prescribes these medications only after a complete telehealth or in-person consultation, medical review, and determination of medical appropriateness by a licensed provider.
These medications are not suitable for everyone. Eligibility requires completing all intake questions, medical history, documentation, and any required lab work.
 
FDA Status & Compounded Medication Disclaimer
FDA-approved versions of Semaglutide and Tirzepatide (e.g., Wegovy, Ozempic, Zepbound, Mounjaro) may be prescribed when clinically appropriate and available.
 
PharmXHealthOne may also prescribe compounded Semaglutide or compounded Tirzepatide from licensed 503A or 503B compounding pharmacies when FDA-approved products are unavailable or when a prescriber determines compounded alternatives are medically necessary.
 
Compounded medications:

  • Are not FDA-approved products

  • Are prepared by licensed U.S. compounding pharmacies

  • Must comply with state regulations

  • May vary in formulation compared to branded FDA-approved versions

 
Patients will be informed when a prescription is compounded.
 
Risks & Side Effects Disclaimer
Semaglutide and Tirzepatide may cause side effects. Common risks include:

  • Nausea, vomiting, diarrhea, or constipation

  • Decreased appetite

  • Injection-site reactions

  • Fatigue or headache

  • Bloating or mild stomach discomfort

 
Serious but less common risks may include:

  • Pancreatitis

  • Gallbladder disease

  • Kidney issues

  • Hypoglycemia (especially if combined with other glucose-lowering agents)

  • Possible thyroid C-cell tumor risk (observed in rodents; relevance to humans unknown)

 
Patients must immediately report:

  • Severe abdominal pain

  • Signs of dehydration

  • Persistent vomiting

  • Swelling in neck or difficulty breathing

  • Allergic reactions

 
These medications should NOT be used by individuals with:

  • Personal or family history of medullary thyroid carcinoma (MTC)

  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

  • Active pancreatitis

 
Pregnancy, Breastfeeding & Fertility Disclaimer
Semaglutide and Tirzepatide are not recommended during pregnancy or while breastfeeding.
Patients must notify the provider immediately if:

  • They become pregnant

  • Are planning pregnancy

  • Suspect pregnancy

 
Female patients of reproductive age may be required to confirm pregnancy status.
 
Lab Testing & Follow-Up Compliance
Providers may require baseline and follow-up laboratory tests, including:

  • A1C

  • Liver function

  • Kidney function

  • Lipid profile

 
Failure to comply with required labs or follow-up visits may result in treatment suspension or discontinuation.
 
No Guarantee of Weight Loss
Every patient responds differently. PharmXHealthOne does not guarantee any specific weight loss results, speed of results, or treatment outcomes. Weight reduction depends on medication response, adherence to the program, nutrition, physical activity, and individual metabolic factors.
 
Results presented in marketing materials are estimates only and not promises.
 
State-Specific Prescribing Restrictions
PharmXHealthOne complies with all federal and state telemedicine prescribing laws. Depending on the patient’s state of residence:
 
The following may apply:

  • Required in-state labs

  • Limitations on prescribing compounded medications

  • Restrictions on telehealth prescribing for certain controlled or non-controlled medications

  • Requirement for initial in-person physical exam (certain states)

 
Examples:
California: Additional documentation of medical necessity may be required for compounded medications.
 
New York: Strict compounding and telehealth prescribing oversight; compounded peptides/medications may have restrictions.
 
Texas: Telehealth prescribing permitted but may require additional follow-up or lab compliance.
 
Alabama: Enhanced telemedicine rules may require more documentation before prescribing.
 
Arkansas: Some medications or compounded formulations may require initial in-person exam unless statutory exemptions apply.
 
Patients will be informed if state laws prevent us from prescribing specific formulations.
 
Insurance Coverage Disclaimer
Semaglutide and Tirzepatide—especially compounded versions—are often not covered by insurance plans.
Patients are responsible for:

  • All program fees

  • Medication costs

  • Follow-up visits

  • Required laboratory tests

 
Drug Interactions & Safety Disclaimer
Patients must disclose:

  • All current medications

  • Over-the-counter supplements

  • Vitamins, peptides, and herbs

  • All medical conditions

 
Failure to provide full medical information may increase treatment risk and may result in PharmXHealthOne declining or discontinuing treatment.
 
PharmXHealthOne Provider Discretion
All prescriptions are issued solely at the discretion of the licensed medical provider.
PharmXHealthOne reserves the right to:

  • Decline prescribing

  • Modify treatment

  • Suspend treatment

  • Require additional labs or documentation

  • Discontinue treatment if safety concerns arise

Completion of a consultation does not guarantee prescription approval.

bottom of page